

1 **Long-Term Opioid Use and Emotional, Cognitive, and Sensorimotor Function**
2 **in Chronic Back Pain**

3
4 Gaelle Rached MD MSc^{1,2}, Andrew D. Vigotsky MS^{1,2,3}, Paulo Branco PhD^{1,2}, Rami Jabakhanji
5 PhD^{1,2}, Thomas J. Schnitzer MD PhD^{1,4}, A. Vania Apkarian PhD^{1,2,4,5},
6 and Marwan N. Baliki PhD^{1,4,6}

7
8 ¹ Center for Translational Pain Research, and Center of Excellence for Chronic Pain and Drug
9 Abuse Research, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

10 ² Department of Neuroscience, Northwestern University Feinberg School of Medicine, Chicago,
11 IL, USA

12 ³ Departments of Biomedical Engineering and Statistics, Northwestern University, Evanston, IL,
13 USA

14 ⁴ Department of Physical Medicine and Rehabilitation, Northwestern University Feinberg School
15 of Medicine, Chicago, IL, USA

16 ⁵ Department of Anesthesiology, Northwestern University Feinberg School of Medicine,
17 Chicago, IL, USA

18 ⁶ Shirley Ryan Ability Lab, Chicago, IL, USA

19 Correspondence to: Dr A.V. Apkarian

20 E-mail : a-apkarian@northwestern.edu

21

22 **Abstract**

23 This study examines cognitive, emotional, sensory, and motor function in patients with
24 chronic back pain (CBP) with and without long-term opioid exposure (CBP+O vs. CBP–O) and
25 the influence of race and sex on these outcomes. We recruited 64 CBP+O (mean 7.4 years of
26 opioid use) and 64 matched CBP–O. We collected pain intensity, pain duration, NIH Toolbox
27 outcomes, and measures of opioid use: dosage, duration, blood levels, and withdrawal
28 symptoms. We compared both groups to a normative sample, examined sex and race influences
29 separately, and related CBP+O’s NIH Toolbox outcomes to their opioid use measures.

30 CBP+O reported greater pain interference and poorer emotional function. Sex moderated
31 opioid exposure’s effects on cognitive performance and social satisfaction, while race moderated
32 motor dexterity and taste outcomes. In CBP+O, 1) opioid dosage was associated with cognitive
33 speed and sensory performance; 2) blood levels of opioids corresponded with poorer attention,
34 motor endurance, and more severe stress and negative affect; 3) opioid use duration was related
35 to improved working memory; while 4) higher withdrawal symptoms were associated with
36 poorer cognitive performance, worsened negative emotions, and decreased grip strength.

37 The study demonstrates both positive and negative outcomes associated with long-term
38 opioid use in CBP, highlighting the need to consider sex- and race-related factors when assessing
39 function in this population.

40 **Introduction**

41 The opioid epidemic is a major public health crisis affecting the United States, with
42 devastating health, economic, and societal costs ¹. Despite controversial evidence of efficacy,
43 opioids are widely used for treating chronic pain and thus contribute to the ongoing epidemic ²⁻⁶.
44 Chronic pain and opioid use have largely been studied independently compared to healthy controls,
45 although they are intertwined. Chronic pain is associated with impairments in memory, attention,
46 processing speed, and executive functioning ^{7, 8}. Similarly, long-term opioid prescription use is
47 associated with declines in global cognitive performance, particularly in memory, language, and
48 attention ⁹. In addition, prescription opioid misuse and chronic pain worsen negative affect and
49 psychological well-being ¹⁰.

50 Despite overwhelming evidence that chronic pain and long-term opioid use separately
51 impact multiple psychological domains, insufficient research characterizes both conditions
52 concurrently. Consequently, the characteristics of long-term opioid use in chronic pain patients
53 compared to chronic pain without opioids are poorly understood. Here, we investigated the effect
54 of opioids on patients with chronic back pain (CBP) by comparing CBP on long-term opioids
55 (CBP+O) to matched CBP without opioids (CBP-O) using a standard multidimensional
56 assessment tool, the NIH toolbox, which measures cognitive, emotional, sensory, and motor
57 function ¹¹, providing a holistic picture of neurological and behavioral health. As the patients
58 studied were 58% female and 30% black, we also interrogated sex and race influences on NIH
59 toolbox outcomes. Finally, we examined how opioid dosage, opioid blood levels, opioid duration,
60 and withdrawal symptoms related to the NIH toolbox scores in CBP+O.

61

62 **Methods**

63 ***Recruitment***

64 We recruited 64 CBP+O patients (pain duration > 6 months, mean = 16.5 years) on opioid therapy
65 for at least three months. We selected 64 CBP-O patients (mean pain duration = 16.7 years) from
66 a previously recruited sample (Figure 1). Patients were matched on age, sex, pain intensity, and
67 pain duration using optimal matching¹² (Table 1). All participants were fluent in English, over 18
68 years of age, and could understand instructions and questionnaires. Recruitment was from the
69 Northwestern Medicine (NM) healthcare system and Shirley Ryan Ability Lab. Our exclusion
70 criteria included (1) treatment with a spinal cord stimulator; (2) diagnosis of rheumatoid arthritis,
71 ankylosing spondylitis, acute vertebral fractures, fibromyalgia, low back/spine oncologic history,
72 and other comorbid neurological disorders, including major depression and psychiatric disorder
73 requiring treatment; (3) involvement in litigation regarding their back pain, having a disability
74 claim, or receiving workman's compensation; (4) significant comorbid diseases such as
75 uncontrolled hypertension, unstable diabetes mellitus, renal insufficiency, congestive heart failure,
76 coronary or peripheral vascular disease, chronic obstructive lung disease, or malignancy; (5)
77 pregnancy; (6) Beck Depression Inventory (BDI) > 28. The protocols were approved by
78 Northwestern University IRB (STU00207384, STU00205398).

79

80 ***Measures***

81 We collected demographic information from participants, including age, sex, race, and pain
82 intensity (0–10 numeric rating scale, NRS) and duration. Participants completed the four
83 neuropsychological domains of the NIH toolbox: cognition, emotion, motor, and sensation¹¹.

84 Tests requiring personal interaction between the experimenter and participants were skipped
85 during the height of the COVID-19 pandemic.

86 For the CBP+O group, we collected opioid duration and dosage, which we converted to
87 morphine milligram equivalent (MME) using CDC's conversion factors ¹³. We also collected
88 plasma to quantify systemic opioid levels. Plasma opioid concentrations were converted to a
89 relative opiate equivalent (ROE), taking into consideration the affinity of each opioid to the mu-
90 opioid receptor (MOR) ¹⁴ and respective molar weights ¹⁵⁻²². Withdrawal was assessed by the
91 Subjective Opiate Withdrawal Scale (SOWS), a self-report questionnaire to rate common signs
92 and symptoms of opiate withdrawal ²³.

93

94 ***Blood sample collection, analysis, and ROE calculations***

95 We also collected blood samples from participants to quantify systemic levels of opioids. The
96 concentrations of eight analytes (oxymorphone, hydromorphone, oxycodone, hydrocodone,
97 fentanyl, buprenorphine, methadone and tramadol) and the presence of three others (morphine,
98 codeine, and heroin) in plasma were determined by liquid chromatography-tandem mass
99 spectrometry after sample preparation by solid-phase extraction, using deuterated analogs
100 (oxymorphone-D3, hydromorphone-D6, oxycodone-D6, hydrocodone-D6, buprenorphine-D4,
101 methadone-D3, and tramadol-C13D3) as internal standards, based on the method reported by
102 Langman et al ²⁴. One hundred microliters of the plasma sample were diluted with 300 uL of 1%
103 acetic acid, vortexed and loaded onto a Phenomenex Strata-X-Drug B 96-well plate. After washing
104 with 100 mM sodium acetate buffer and methanol, the analytes were eluted with an ethyl
105 acetate/isopropanol/ammonium hydroxide (7:2:1 v/v/v) mixture and evaporated to dryness under
106 a stream of nitrogen. The samples were reconstituted in 15% methanol in water and analyzed by a

107 Sciex 6500+ Qtrap LC-MS/MS system equipped with a Shimadzu Nexera2 UPLC system.
108 Samples were eluted from a Phenomenex Kinetex 2.6 μm Biphenyl (50 x 2.1 mm) column with a
109 mobile phase consisting of A: water with 0.1 % formic acid and B: methanol with 0.1 % formic
110 acid at a flow rate of 0.6 mL/min with a gradient from 10% B to 85% B in 4.5 min.
111 Samples were run in duplicate, and the average opioid concentration was used. The opioid
112 concentrations were then converted to a relative opiate equivalent (ROE), taking into consideration
113 the affinity of each opioid to the mu-opioid receptor (MOR)¹⁴, and the respective molar weights
114¹⁵⁻²². We realize that limiting tramadol to its MOR affinity excludes other aspects of the tramadol
115 effect; however, we are specifically interested in the opiate activity on MOR. Samples with peak
116 presence of opioids below the lower limit of quantitation were imputed as the halfway point from
117 zero to the measurable lower quantifiable threshold.

118

119 *Statistical Analysis*

120 NIH toolbox differences between CBP+O and CBP-O were analyzed using multiple
121 regression with age, gender, pain intensity, and pain duration included as covariates—the same
122 covariates on which the participants were matched. Because we used one-to-one matching, we
123 calculated cluster-robust variances. For each outcome, each group's score was also compared to
124 normative data using a one-sample *t*-test, with a mean T-score of 50 and a standard deviation of
125 10 in the normative sample. To investigate the effects of sex and race, we performed separate
126 multiple regressions: one with a sex-by-group interaction and another with a race-by-group
127 interaction.

128 To map NIH toolbox scores onto CBP-O's opioid parameters, we calculated rank-based
129 partial correlations (95% CI) between the NIH toolbox outcomes and measures of opioid use,

130 adjusted for age, sex, pain intensity, and pain duration. To do so, (1) all the measures were
131 converted to ranks, (2) opioid use metrics and NIH toolbox metrics were residualized with respect
132 to the covariates, and (3) we calculated Pearson correlation coefficients using the residuals.
133 Measures of opioid use were quantified in terms of opioid dosage (MME), opioid blood level
134 (ROE), opioid duration (years), and opioid withdrawal (SOWS). MME and ROE were log-
135 transformed due to the skewed distributions.

136

137 **Results**

138 We independently evaluated the groups' NIH toolbox outcomes and contrasted the groups
139 with and without sex and race interactions (figure 2). In the cognition domain, Flanker's attentional
140 inhibitory control test was most perturbed in both groups compared to normative values, while
141 picture vocabulary was worse in CBP+O. In the emotion domain, CBP+O was worse than CBP-O
142 on all five tests, especially regarding social satisfaction. All six motor tests were abnormal but with
143 divergent differences: balance and walking endurance were similarly diminished in both groups;
144 grip strength was worse in CBP-O; and dexterity was worse in CBP+O. In the sensation domain,
145 taste was similarly worse than normative values across both groups and pain interference was
146 worse in both groups, but more so in CBP+O.

147 Sex moderated the effects of opioid exposure on social satisfaction, grip strength, and
148 walking endurance. Race moderated the group effect on grip strength, dexterity, stress, working
149 memory, and flanker inhibitory control.

150 Adjusted partial correlations within the CBP+O group examined the influence of opioid
151 use measures on NIH toolbox outcomes (Figure 3): 1) Higher opioid use dosages were related to
152 better processing speed, salt and odor identification, and worse dexterity. 2) Greater opioid blood

153 levels were related to higher stress, decreased well-being, increased negative affect, and
154 diminished walking ability. 3) Longer durations of opioid use were related to better memory
155 performance. 4) More severe opioid withdrawal signs (SOWS) were related to worse vocabulary
156 and memory, worse outcomes for all five emotion measures, lower grip strength and quinine taste,
157 and increased pain interference.

158

159 **Discussion**

160 Our study examined the association of chronic pain and long-term opioid use on cognitive,
161 sensory, emotional, and motor functioning. Both CBP+O and CBP-O experienced more pain
162 interference than the normative sample. Although our study groups were matched on back pain
163 intensity and duration, CBP+O exhibited more pain interference, which we surmise may be related
164 to opioid-induced hyperalgesia^{25, 26}; these effects were not moderated by race and sex. Within
165 CBP+O, pain interference was most strongly related to withdrawal signs, weakly related to opioid
166 dosage (consistent with earlier data²⁷) and opioid blood levels, and appeared to be unrelated to the
167 duration of opioid use (contrary to an earlier report²⁸).

168 The emotional domain of the NIH toolbox was the dimension most perturbed by opioid
169 exposure. All five emotion-related tests exhibited poorer outcomes in CBP+O, especially
170 regarding social satisfaction, which was moderated by sex. Like pain interference, all five
171 measures were associated with withdrawal and less consistently with blood levels of opioids.
172 Given that this is a cross-sectional observational study, causal relationships remain unclear.
173 However, given that pain interference and emotion domain were all related to state measures
174 (blood opioids, withdrawal), it is suggested that the worsening of these outcomes is a consequence
175 of opioid exposure.

176 In the motor domain, some measures were improved, and others were exacerbated in
177 CBP+O. Moreover, these outcomes were differentially moderated by race. In the sensory taste
178 outcomes, both CBP–O and CBP+O showed similar abnormalities moderated by race. In the
179 cognitive domain, CBP+O and CBP–O performed poorly on attentional tasks, consistent with
180 previous studies demonstrating that chronic pain is associated with impaired general cognitive
181 functions^{8, 29, 30}. These results have broad implications for the daily functioning and rehabilitation
182 of individuals with chronic pain. Previous results regarding long-term opioid use and cognition
183 remain contradictory and inconclusive³¹⁻³⁶.

184 Disparities in cognitive performance among individuals with chronic pain relative to race
185 highlight the need for further investigation and consideration of race-related factors when
186 assessing and treating cognitive impairments in this population. Interestingly, sex effects were less
187 prominent than race and included specific outcomes in cognition, emotion, and motor domains.
188 Both factors remain to be studied more thoroughly in the future.

189 This study has three noteworthy limitations. First, our cross-sectional design makes the
190 causality unclear. However, this is partially overcome by our matching and relating outcomes to
191 opioid measures. Second, we excluded patients who have a clinical diagnosis of depression and
192 have a BDI > 28, decreasing the generalizability of our results while allowing us to characterize
193 behavior and functioning in patients with minimal psychiatric confounds. Third, our matched
194 sample comes from a previously recruited sample. Since the data were collected by different
195 people at different time points, potentially affecting our measured values.

196

197

198

199 **Conclusion**

200 Our study provides important insights into the impact of chronic pain and long-term opioid
201 use on various domains of functioning. Chronic pain was associated with cognitive, sensory,
202 emotional, and motor impairments, with attention deficits being a prominent feature. Our results
203 suggest that long-term opioid use may not significantly contribute to cognitive impairments
204 beyond chronic pain itself. However, long-term opioid use is associated with worse emotional
205 functioning. Additionally, our study highlights potential race and sex disparities in cognitive
206 performance and social satisfaction, respectively, among individuals with chronic pain. Overall,
207 our study furthers our understanding of the complex interactions between chronic pain and long-
208 term opioid use in different aspects of patients' lives, which can inform more effective treatment
209 strategies for this patient population.

210

211 **Table 1: Demographic characteristics of patients with chronic back pain not**
212 **consuming opioids (CBP – O) and on long-term opioids (CBP + O)**
213

	CBP - O (N=64)	CBP + O (N=64)	P-value^a
Age (years)			
Mean (SD)	59.3 (12.6)	59.6 (11.2)	0.90
Sex			
Male	28 (43.8%)	24 (37.5%)	0.59
Female	36 (56.3%)	40 (62.5%)	
Race			0.01
Black/African American	20 (31.3%)	20 (31.3%)	
White	33 (51.6%)	43 (67.2%)	
Other	10 (15.6%)	1 (1.6%)	
Missing	1 (1.6%)	0 (0%)	
Pain Intensity (0-10)			
Mean (SD)	5.22 (2.20)	5.33 (1.98)	0.77

	CBP - O (N=64)	CBP + O (N=64)	P-value^c
Pain Duration (years)			
Mean (SD)	16.5 (19.3)	16.7 (12.2)	0.94
Opioid Dosage (MME)			
Mean (SD)	NA	66.5 (196)	NA
Median [Min, Max] ^a	NA	20.0 [5.00, 1440]	
Missing	NA	5 (7.8%)	
Opioid Blood Level (ROE)			
Mean (SD)	NA	0.0146 (0.0736)	NA
Median [Min, Max] ^a	NA	0.000400 [0, 0.552]	
Missing	NA	7 (10.9%)	
Opioid Withdrawal (SOWS)			
Mean (SD)	NA	8.69 (8.42)	NA
Opioid Use Duration (years)			
Mean (SD)	NA	7.36 (6.14)	NA
Opioid Type (N)^b			
Buprenorphine	0	1	NA
Codeine	0	2	NA
Fentanyl Patch	0	3	NA
Hydrocodone	0	25	NA
Hydromorphone	0	1	NA
Methadone	0	2	NA
Morphine	0	3	NA
Oxycodone	0	11	NA
Oxymorphone	0	1	NA
Tapentadol	0	1	NA
Tramadol	0	25	NA

214 ^a MME and ROE were log-transformed due to their respective skewed distribution; thus, median, and interquartile range (IQR) is also
 215 reported.


216 ^b Eleven patients were taking two types of opioids thus the total is higher than 100%.

217 ^c P values were calculated using a t-test for continuous variables and chi-square test for categorical variables. NA = not available.

218

219 **Figures & Legends**

220



221

222

223 **Figure 1: Recruitment flowchart of patients with chronic back pain not consuming**

224 **opioids (CBP – O) and on long-term opioids (CBP + O).**

225 .

226

227



228

229

230

231

A



232
233

234 **Figure 2: The Emotional, Cognitive, and Sensorimotor Scores in Patients with**
 235 **Chronic Back Pain with (CBP+O) or without Long-Term Opioid Use (CBP-O) and**
 236 **Their Relationships with Sex and Race.**


237 (A) Estimated marginal means (95% CI) of the NIH toolbox components for patients with
 238 chronic back pain with (green, $n=64$) and without (pink, $n=64$) long-term opioids. Point
 239 estimates and their CIs were obtained using a linear regression adjusted for age, sex,
 240 pain intensity, and pain duration with cluster-robust variances. The grey line indicates the

241 mean in a normative sample (normative T-score = 50 ± 10 , $n = 1000$). Each group can
242 thus be directly compared to the normative sample using their estimate and 95% CI. The
243 number of participants per group per measure is shown. The second column shows group
244 differences (CBP+O minus CBP-O, 95% CI) for each subscale. Data points with CIs not
245 crossing the line on 0 indicate $P < 0.05$. The third column shows opioid group by sex
246 interactions (95% CI). Positive values indicate that the CBP+O minus CBP-O is greater
247 in females, and negative values indicate the opposite (CBP+O minus CBP-O is greater
248 in males). The fourth column shows the opioid group by race interaction (95% CI); positive
249 values indicate that CBP+O minus CBP-O is greater in blacks, and negative values
250 indicate the opposite (CBP+O minus CBP-O is greater in whites). We did not include the
251 “Other” category for race in the analysis. **(B)** Group differences in Grip-Strength
252 Dominant, Social Satisfaction, 2min Walk Endurance stratified by sex. **(C)** Group
253 differences in Grip-Strength Dominant, Social Satisfaction, 2min Walk Endurance
254 stratified by race. Box plots show the upper and lower quartiles and medians, and point
255 estimates show the mean.

256

257

258



259
 260 **Figure 3: The Relationship between Emotional, Cognitive, and Sensorimotor**
 261 **Scores and Opioid Dosage, Opioid Blood Level, Opioid Use Duration, and**
 262 **Withdrawal Signs in Patients with Chronic Back Pain with Long-Term Opioid Use**
 263 **(CBP+O).**

264 **(A)** Partial rank correlations (95% CI) between the NIH Toolbox items and measures of
 265 opioid use adjusted for age, sex, pain intensity, and pain duration. Measures of opioid
 266 use are quantified in terms of opioid dosage (log(MME)), opioid blood level (log(ROE)),
 267 opioid duration (years) and opioid withdrawal (SOWS). The numbers of participants per
 268 NIH Toolbox test and per opioid use measure are represented on the plot. **(B)** Scatter
 269 plots showing the partial rank correlations between some NIH Toolbox items and
 270 measures of opioid use. Nine-Hole Pegboard Dexterity-Dominant was correlated with

271 opioid dosage (log(MME)), 2-Minute Walk Endurance with opioid blood level (log(ROE)),
272 List Sorting Working Memory with opioid duration, and Negative Affect and Picture
273 Vocabulary with Withdrawal Severity (SOWS). Solid lines in the scatter plots show fitted
274 lines and shaded areas are 95% confidence intervals. Since we used partial rank
275 correlations, the axes in (B) are based on residualized ranks rather than original units.

276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302

303 **Acknowledgments:**

304 This work made use of the Mary Beth Donnelley Clinical Pharmacology Core at Northwestern
305 University, which has received support from the NIH (1S10OD012016-01 / 1S10RR019071-
306 01A1), Soft and Hybrid Nanotechnology Experimental (SHyNE) Resource (NSF ECCS-
307 1542205), the State of Illinois, and the International Institute for Nanotechnology (IIN).

308 Meghan Ford, data collection

309 Elizabeth Yan, data collection

310 Maryam Abdallah, data collection

311 Byron K Yip, data collection

312 Santiago Espinosa, data collection

313 Rahia Parveen Shuaib, data collection

314 **References**

315 1. Volkow ND, Blanco C. The changing opioid crisis: development, challenges and
316 opportunities. *Mol Psychiatry*. 2021;26(1):218-33. Epub 20200204. doi: 10.1038/s41380-020-
317 0661-4. PubMed PMID: 32020048; PMCID: PMC7398847.

318 2. Nury E, Schmucker C, Nagavci B, Motschall E, Nitschke K, Schulte E, Wegwarth O,
319 Meerpohl JJ. Efficacy and safety of strong opioids for chronic noncancer pain and chronic low
320 back pain: a systematic review and meta-analyses. *Pain*. 2022;163(4):610-36. Epub 2021/07/31.
321 doi: 10.1097/j.pain.0000000000002423. PubMed PMID: 34326292.

322 3. Volkow ND, McLellan AT. Opioid Abuse in Chronic Pain — Misconceptions and
323 Mitigation Strategies. *New England Journal of Medicine*. 2016;374(13):1253-63. doi:
324 10.1056/NEJMra1507771. PubMed PMID: 27028915.

- 325 4. Nagpal AS, Eckmann M, Weinstein SM. Maintaining Opioid Prescription for Chronic
326 Back Pain: Pro Versus Con. *PM R*. 2018;10(1):83-9. doi: 10.1016/j.pmrj.2017.12.002. PubMed
327 PMID: 29413121.
- 328 5. Voon P, Karamouzian M, Kerr T. Chronic pain and opioid misuse: a review of reviews.
329 *Subst Abuse Treat Prev Policy*. 2017;12(1):36. Epub 20170815. doi: 10.1186/s13011-017-0120-
330 7. PubMed PMID: 28810899; PMCID: PMC5558770.
- 331 6. Dahlhamer JM, Connor EM, Bose J, Lucas JL, Zelaya CE. Prescription Opioid Use Among
332 Adults With Chronic Pain: United States, 2019. *Natl Health Stat Report*. 2021(162):1-9. Epub
333 2021/09/16. PubMed PMID: 34524076.
- 334 7. Higgins DM, Martin AM, Baker DG, Vasterling JJ, Risbrough V. The Relationship
335 Between Chronic Pain and Neurocognitive Function: A Systematic Review. *Clin J Pain*.
336 2018;34(3):262-75. doi: 10.1097/ajp.0000000000000536. PubMed PMID: 28719507; PMCID:
337 PMC5771985.
- 338 8. Moriarty O, McGuire BE, Finn DP. The effect of pain on cognitive function: A review of
339 clinical and preclinical research. *Progress in Neurobiology*. 2011;93(3):385-404. doi:
340 <https://doi.org/10.1016/j.pneurobio.2011.01.002>.
- 341 9. Warner NS, Hanson AC, Schulte PJ, Habermann EB, Warner DO, Mielke MM.
342 Prescription opioids and longitudinal changes in cognitive function in older adults: A population-
343 based observational study. *Journal of the American Geriatrics Society*. 2022;70(12):3526-37. doi:
344 <https://doi.org/10.1111/jgs.18030>.
- 345 10. Martel MO, Dolman AJ, Edwards RR, Jamison RN, Wasan AD. The Association Between
346 Negative Affect and Prescription Opioid Misuse in Patients With Chronic Pain: The Mediating

- 347 Role of Opioid Craving. The Journal of Pain. 2014;15(1):90-100. doi:
348 <https://doi.org/10.1016/j.jpain.2013.09.014>.
- 349 11. NIH. NIH Toolbox® Scoring and Interpretation Guide for the iPad: National Institutes of
350 Health and Northwestern University
351 ; 2021 [updated 5/25/2021; cited 2022 9/8/2022].
- 352 12. Ho D, Imai K, King G, Stuart EA. MatchIt: Nonparametric Preprocessing for Parametric
353 Causal Inference. Journal of Statistical Software. 2011;42(8):1 - 28. doi: 10.18637/jss.v042.i08.
- 354 13. Prevention CfDcA. Analyzing prescription data and morphine milligram equivalents
355 (MME)2021.
- 356 14. Volpe DA, Tobin GAM, Mellon RD, Katki AG, Parker RJ, Colatsky T, Kropp TJ, Verbois
357 SL. Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid
358 drugs. Regulatory Toxicology and Pharmacology. 2011;59(3):385-90. doi:
359 <https://doi.org/10.1016/j.yrtph.2010.12.007>.
- 360 15. Information NCfB. PubChem Compound Summary for CID 5284604, Oxymorphone.
361 2022.
- 362 16. Information NCfB. PubChem Compound Summary for CID 5284603, Oxycodone2022.
- 363 17. Information NCfB. PubChem Compound Summary for CID 3345, Fentanyl2022.
- 364 18. Information NCfB. PubChem Compound Summary for CID 5284570,
365 Hydromorphone2022.
- 366 19. Information NCfB. PubChem Compound Summary for CID 5284569, Hydrocodone2022.
- 367 20. Information NCfB. PubChem Compound Summary for CID 5284371, Codeine2022.
- 368 21. Information NCfB. PubChem Compound Summary for CID 33741, Tramadol2022.
- 369 22. Information NCfB. PubChem Compound Summary for CID 4095, Methadone2022.

- 370 23. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new
371 rating scales for opiate withdrawal. *Am J Drug Alcohol Abuse*. 1987;13(3):293-308. doi:
372 10.3109/00952998709001515. PubMed PMID: 3687892.
- 373 24. Langman LJ, Korman E, Stauble ME, Boswell MV, Baumgartner RN, Jortani SA.
374 Therapeutic monitoring of opioids: a sensitive LC-MS/MS method for quantitation of several
375 opioids including hydrocodone and its metabolites. *Ther Drug Monit*. 2013;35(3):352-9. doi:
376 10.1097/FTD.0b013e318283e29a. PubMed PMID: 23666565.
- 377 25. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of
378 opioid-induced hyperalgesia. *Pain Physician*. 2011;14(2):145-61. PubMed PMID: 21412369.
- 379 26. Wilson SH, Hellman KM, James D, Adler AC, Chandrakantan A. Mechanisms, diagnosis,
380 prevention and management of perioperative opioid-induced hyperalgesia. *Pain Manag*.
381 2021;11(4):405-17. Epub 20210329. doi: 10.2217/pmt-2020-0105. PubMed PMID: 33779215;
382 PMCID: PMC8023328.
- 383 27. Denawa Y, Kurtz W, Conermann T. The Social and Functional Implications of High-
384 Versus Low-Dose Opioids on Chronic Non-Cancer Pain. *Pain Physician*. 2019;22(4):401-11.
385 PubMed PMID: 31337176.
- 386 28. Morasco BJ, Yarborough BJ, Smith NX, Dobscha SK, Deyo RA, Perrin NA, Green CA.
387 Higher Prescription Opioid Dose is Associated With Worse Patient-Reported Pain Outcomes and
388 More Health Care Utilization. *The Journal of Pain*. 2017;18(4):437-45. doi:
389 <https://doi.org/10.1016/j.jpain.2016.12.004>.
- 390 29. Prefontaine K, Rochette A. A Literature Review on Chronic Pain: The Daily Overcoming
391 of a Complex Problem. *British Journal of Occupational Therapy*. 2013;76(6):280-6. doi:
392 10.4276/030802213x13706169932905.

- 393 30. Sjøgren P, Christrup LL, Petersen MA, Højsted J. Neuropsychological assessment of
394 chronic non-malignant pain patients treated in a multidisciplinary pain centre. *Eur J Pain*.
395 2005;9(4):453-62. Epub 20041105. doi: 10.1016/j.ejpain.2004.10.005. PubMed PMID: 15979026.
- 396 31. Kendall SE, Sjøgren P, Pimenta CAM, Højsted J, Kurita GP. The cognitive effects of
397 opioids in chronic non-cancer pain. *Pain*. 2010;150(2):225-30. doi: 10.1016/j.pain.2010.05.012.
398 PubMed PMID: 20554115.
- 399 32. Jamison RN, Schein JR, Vallow S, Ascher S, Vorsanger GJ, Katz NP. Neuropsychological
400 effects of long-term opioid use in chronic pain patients. *J Pain Symptom Manage*. 2003;26(4):913-
401 21. doi: 10.1016/s0885-3924(03)00310-5. PubMed PMID: 14527760.
- 402 33. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy
403 for chronic peripheral and central neuropathic pain. *N Engl J Med*. 2003;348(13):1223-32. doi:
404 10.1056/NEJMoa021420. PubMed PMID: 12660386.
- 405 34. Tassain V, Attal N, Fletcher D, Brasseur L, Dégieux P, Chauvin M, Bouhassira D. Long
406 term effects of oral sustained release morphine on neuropsychological performance in patients
407 with chronic non-cancer pain. *Pain*. 2003;104(1-2):389-400. doi: 10.1016/s0304-3959(03)00047-
408 2. PubMed PMID: 12855350.
- 409 35. Schiltenswolf M, Akbar M, Hug A, Pfuller U, Gantz S, Neubauer E, Flor H, Wang H.
410 Evidence of Specific Cognitive Deficits in Patients with Chronic Low Back Pain under Long-Term
411 Substitution Treatment of Opioids. *Pain physician*. 2014;17:9-20. doi: 10.36076/ppj.2014/17/9.
- 412 36. Lee DM, Pendleton N, Tajar A, O'Neill TW, O'Connor DB, Bartfai G, Boonen S,
413 Casanueva FF, Finn JD, Forti G, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean MEJ,
414 Punab M, Silman AJ, Vanderschueren D, Moseley CM, Wu FCW, McBeth J. Chronic widespread
415 pain is associated with slower cognitive processing speed in middle-aged and older European men.

416 Pain. 2010;151(1):30-6. Epub 20100619. doi: 10.1016/j.pain.2010.04.024. PubMed PMID:
417 20646831.
418